Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics.
Bourner J. et al, (2025), Emerging infectious diseases, 31, 9 - 16
Improving clinical care of patients in Nipah outbreaks: moving beyond 'compassionate use'.
Hassan MZ. et al, (2025), The Lancet regional health. Southeast Asia, 33
Clinical characterisation and outcomes of human clade IIb mpox virus disease - a European multicentre observational cohort study (MOSAIC).
Pesonel E. et al, (2025), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
The priority review voucher: a misconceived quid pro quo.
Olliaro P. and Torreele E., (2024), BMJ Glob Health, 9
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials
Chan XHS. et al, (2024), The Lancet Microbe, 101002 - 101002
Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa.
van Dorst PWM. et al, (2024), Applied health economics and health policy, 22, 701 - 715
Impact of a package of point-of-care diagnostic tests, a clinical diagnostic algorithm and adherence training on antibiotic prescriptions for the management of non-severe acute febrile illness in primary health facilities during the COVID-19 pandemic in Burkina Faso.
Kiemde F. et al, (2024), BMC infectious diseases, 24
An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus an aminoglycoside + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial-an update to the published protocol.
Randremanana RV. et al, (2024), Trials, 25
At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods.
Mesinovic M. et al, (2024), Scientific reports, 14
Nipah virus disease: what can we do to improve patient care?
Hassan MZ. et al, (2024), The Lancet. Infectious diseases, 24, e463 - e471
Challenges in clinical diagnosis of Clade I Mpox: Highlighting the need for enhanced diagnostic approaches.
Bourner J. et al, (2024), PLoS neglected tropical diseases, 18
Interpretations of Studies on SARS-CoV-2 Vaccination and Post-acute COVID-19 Sequelae.
Gonçalves BP. et al, (2024), Epidemiology (Cambridge, Mass.), 35, 368 - 371
The facilitators of and barriers to antimicrobial use and misuse in Lalitpur, Nepal: a qualitative study.
Udas S. et al, (2024), BMC public health, 24
Diagnostic tests for human Schistosoma mansoni and Schistosoma haematobium infection: a systematic review and meta-analysis.
Vaillant MT. et al, (2024), The Lancet. Microbe, 5, e366 - e378
Systematic Review of Scales for Measuring Infectious Disease–Related Stigma
Paterson A. et al, (2024), Emerging Infectious Diseases, 30
Involving patients in drug development for Neglected Tropical Diseases (NTDs): A qualitative study exploring and incorporating preferences of patients with cutaneous leishmaniasis into Target Product Profile development.
Castro MDM. et al, (2024), PLoS neglected tropical diseases, 18
Mpox: The alarm went off. Have we gone back to sleep?
Olliaro P. et al, (2024), PLOS Neglected Tropical Diseases, 18, e0011871 - e0011871
Expanded Access Programme for the use of tecovirimat for the treatment of monkeypox infection: A study protocol for an Expanded Access Programme.
Bourner J. et al, (2024), PloS one, 19